The Department of Defense is offering the Duchenne Muscular Dystrophy Research Program (DMDRP) Therapeutic Idea Award for fiscal year 2015. This grant supports early-stage, high-risk/high-reward research ideas with the potential to advance novel therapeutics for DMD. Emphasis is placed on innovation and impact, with projects focusing on new paradigms, biomarker studies, and significant potential to impact DMD therapeutics. The award does not require preliminary data but prioritizes well-formulated, testable hypotheses. The grant specifically encourages the discovery and qualification of minimally invasive biomarkers to aid in the development of DMD treatments. The closing date for applications is October 21, 2015.
Opportunity ID: 277039
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-DMDRP-TIA |
| Funding Opportunity Title: | DoD Duchenne Muscular Dystrophy Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 04, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Oct 21, 2015 |
| Current Closing Date for Applications: | Oct 21, 2015 |
| Archive Date: | Nov 20, 2015 |
| Estimated Total Program Funding: | $480,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The DMDRP Therapeutic Idea Award mechanism was offered in FY12 and FY14, and is being offered again in FY15. It is designed to promote new ideas that are still in the early stages of development with the potential to yield high-impact data and new avenues of investigation for novel therapeutics for DMD treatment. This award mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in DMD therapeutics. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data. Innovation and Impact are the most important aspects of the Therapeutic Idea Award. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapies for DMD (e.g., drug repurposing studies). Innovative research may include high-risk approaches to DMD research. Research that is investigating the next logical step or is an incremental advance upon published data is not considered innovative. Impact: Research that has high potential to significantly impact development of therapeutics for DMD. Biomarker Studies For projects addressing the FY15 DMDRP Focus Area of “discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers,” a biological marker, or biomarker, is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention.1 For the purpose of this award, biomarker qualification is defined as the evidentiary fit-for-purpose process of correlating a biomarker with the effects of an agent on biological processes and clinical endpoints.2 The DMDRP encourages the discovery and study of biomarkers that can be detected through minimally invasive procedures (e.g., blood, urine, tissue, imaging, etc.). Examples of biomarkers may include signatures of genetic or epigenetic changes, specifically expressed genes, proteins, or metabolites, and molecular, physiological, and/or imaging entities, among others. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 277039 Full Announcement-1 -> dmdrp_fy15_tia_pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00217247 | Jun 04, 2015 | Oct 21, 2015 | View |
Package 1
Mandatory forms
277039 RR_SF424_2_0-2.0.pdf
277039 RR_Budget_1_3-1.3.pdf
277039 RR_KeyPersonExpanded_2_0-2.0.pdf
277039 PerformanceSite_2_0-2.0.pdf
Optional forms
277039 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
